Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Outlook Therapeutics trims workforce by 23% to fund Lytenava launch
Outlook Therapeutics, a biopharmaceutical company specialising in retina disease treatments, has announced a 23% workforce reduction as part of strategic cost-saving measures. This move is ... Read More
FDA approves Checkpoint Therapeutics’ Unloxcyt for advanced cSCC
Shares of Checkpoint Therapeutics, Inc. rose 4.6% to $3.84 in post-market trading after the US Food and Drug Administration (FDA) approved Unloxcyt (cosibelimab-ipdl) treatment for ... Read More
FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia
Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in the treatment of classic congenital adrenal hyperplasia ... Read More
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment options in Europe. The European Medicines Agency’s ... Read More
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific antibody aimed at tackling acute myeloid leukemia ... Read More
Trevi Therapeutics announces positive results for Haduvio in Phase 2b CORAL study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has reported a positive outcome from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b trial. ... Read More
Keros Therapeutics adjusts TROPOS trial of cibotercept amid safety concerns
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced significant changes to its Phase 2 TROPOS trial evaluating cibotercept safety concerns in patients with pulmonary ... Read More
Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial
Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), for ... Read More
AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed ... Read More
UniQure shares surge as FDA aligns on accelerated approval pathway for AMT-130 in Huntington’s disease
UniQure, Huntington’s disease, gene therapy, FDA, accelerated approval pathway, regenerative medicine designation, AMT-130, Biologics License Application, neurodegenerative diseases, cUHDRS, Phase I/II studies, neurofilament light chain, ... Read More